CCA
TBPH

Checchi Capital Advisers’s Theravance Biopharma TBPH Stock Holding History

Checchi Capital Advisers’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-2
Closed – – 1104
2016
Q2 		$0 Hold
2
– – ﹤0.01% 1631
2016
Q1 		$0 Buy
+2
New +$33 ﹤0.01% 1610

Other funds holding TBPH

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Checchi Capital Advisers's TBPH Position: Q3 2016 in Review

Checchi Capital Advisers sold out of Theravance Biopharma (TBPH) in Q3 2016, closing a stake of 2 shares.

Checchi Capital Advisers first reported a position in TBPH in Q1 2016 and held it in 2 quarters. The position peaked at $0 in Q2 2016. 100 funds tracked by Wall St. Rank hold TBPH as of Q3 2016.

  • Checchi Capital Advisers reported no remaining Theravance Biopharma position as of Q3 2016 after selling out during the quarter.
  • Checchi Capital Advisers sold 2 Theravance Biopharma shares in Q3 2016.
  • Checchi Capital Advisers first reported a position in Theravance Biopharma in Q1 2016 and held it in 2 quarters.
  • Checchi Capital Advisers's Theravance Biopharma position peaked at $0 in Q2 2016.
  • 100 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2016.

Based on Checchi Capital Advisers's 13F filing for Q3 2016, filed 10 Nov 2016.